topleft topright topcenter
printpage

Professional Resources

References

  1. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis. 2001;32:1319-1324.
  2. Betts R, Glasmacher A, Maertens J, et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer. 2006;106:466-473.
  3. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica. 2006;91:986-989.
  4. Cordonnier C, Calandra T. The first European conference on infections in leukaemia: why and how? Eur J Cancer Suppl. 2007;5:2-4.
  5. Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood. 2003;101:3365-3372.
  6. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348-359.
  7. Data on file. Schering Corporation; Kenilworth, NJ.
  8. Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood. 2003;102:827-833.
  9. Groll AH, Walsh TJ. Antifungal chemotherapy: advances and perspectives. Swiss Med Wkly. 2002;132:303-311.
  10. Groll AH, Walsh TJ. Invasive fungal infections in the neutropenic cancer patient. Abstr Hematol Oncol. 2003;6:18-26.
  11. Hamza NS, Ghannoum MA, Lazarus HM. Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2004;34:377-389.
  12. Herbrecht R, Denning DW, Patterson TF, et al, for the Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
  13. Ito JI, Chandrasekar PH, Hooshmand-Rad R. Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA). Bone Marrow Transplant. 2005;36:873-877.
  14. Lin S-J, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358-366.
  15. Lortholary O, Dupont B. Antifungal prophylaxis during neutropenia and immunodeficiency. Clin Microbiol Rev. 1997;10:477-504.
  16. Lyman GH. Risks and consequences of chemotherapy-induced neutropenia. Clin Cornerstone. 2006;8(suppl):S12-S18.
  17. Maertens J, Frére P, Lass-Flörl C, Heinz W, Cornely O. 2007 update of the ECIL-1 guidelines for antifungal prophylaxis in leukemia patients, including allogeneic HSCT recipients [slide presentation]. Developed during the 2nd European Conference on Infections in Leukemia (ECIL-2); September 28-29, 2007; Juan-les-Pins, France. Available at: http://www.eortc.be/. Accessed on July 30, 2008.
  18. Martino R, Subira M, Rovirá M, et al, and the alloPBSCT Infectious/Non-infectious Complications Subcommittees of the Grupo Español de Trasplante Hematopoyético (GETH). Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol. 2002;116:475-482.
  19. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogenic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358-4366.
  20. Maschmeyer G. New antifungal agents–treatment standards are beginning to grow old. J Antimicrob Chemother. 2002;49:239-241.
  21. Mühlemann K, Wenger C, Zenhäusern R, Täuber MG. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia. 2005;19:545-550.
  22. Mycamine (micafungin sodium) intravenous infusion Prescribing Information. Astellas Pharma, Inc; Tokyo, Japan; January 2008.
  23. Nath DS, Kandaswamy R, Gruessner R, Sutherland DER, Dunn DL, Humar A. Fungal infections in transplant recipients receiving alemtuzumab. Transplant Proc. 2005;37:934-936.
  24. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology: prevention and treatment of cancer-related infections. V.1.2008. Available at: http://www.nccn.org/professionals/physician_gls/PDF/infections.pdf. Published January 16, 2008. Accessed June 2008.
  25. NOXAFIL® (posaconazole) Prescribing Information. Schering Corporation; Kenilworth, NJ; June 2008.
  26. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91:1068-1075.
  27. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol. 2000;110:273-284.
  28. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N; and The Canadian Fluconazole Prophylaxis Study Group. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis. 1999;28:331-340.
  29. Segal BH, Almyroudis NG, Battiwalla M, et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis. 2007;44:402-409.
  30. Singh N, Gayowski T, Wagener M, Marino IR, Yu VL. Pulmonary infections in liver transplant recipients receiving tacrolimus. Changing pattern of microbial etiologies. Transplantation. 1996;61:396-401.
  31. Siwek G, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis. 2004;39:584-587.
  32. Skiest DJ, Vazquez JA, Anstead GM, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis. 2007;44:607-614.
  33. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335-347.
  34. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis. 2007;44:531-540.
  35. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis. 2006;42:1179-1186.
  36. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327-360. Available at: http://www.idsociety.org/content.aspx?id=2656. Accessed January 18, 2008.
  37. Warnock DW. Fungal infections in neutropenia: current problems and chemotherapeutic control. J Antimicrob Chemother. 1998;41(suppl D):95-105.
  38. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci. 2004;21:645-653.
  39. Wingard JR. Antifungal chemoprophylaxis after blood and marrow transplantation. Clin Infect Dis. 2002;34:1386-1390.

Important Safety Information

NOXAFIL® has been shown to interact with several medications, including drugs that suppress the immune system, and these reactions may be serious. The product label should be consulted when other drugs are prescribed with NOXAFIL®.

Coadministration with sirolimus or ergot alkaloids is contraindicated. Coadministration with the CYP3A4 substrates terfenadine, astemizole, cisapride, pimozide, halofantrine, or quinidine, is also contraindicated since this may result in increased plasma concentrations of these medicinal products, leading to QTc prolongation and rare occurrences of torsades de pointes.

Serious and rare fatal toxicity from cyclosporine has occurred when taken in combination with NOXAFIL® and therefore reduction of the dose of drugs like cyclosporine or tacrolimus and frequent monitoring of drug levels of these medications are necessary when taking them in combination with NOXAFIL®.

In clinical trials, there were infrequent cases of hepatic reactions (eg, mild to moderate elevations in ALT, AST, alkaline phosphatase, total bilirubin, and/or clinical hepatitis). Rarely, more severe hepatic reactions including cholestasis or hepatic failure including fatalities were reported in patients with serious underlying medical conditions (eg, hematologic malignancies) during treatment with posaconazole. Liver function tests should be monitored at the start of and during the course of therapy. Discontinuation of NOXAFIL® must be considered in patients who experience symptoms consistent with liver disease that may be attributable to NOXAFIL®.

The safety and effectiveness of NOXAFIL® in patients below the age of 13 years old have not been established.

The most common treatment-related serious adverse events (1% each) in the combined prophylaxis studies were bilirubinemia, increased hepatic enzymes, hepatocellular damage, nausea, and vomiting.

In the pooled prophylaxis safety analysis, fever, headache, anemia, diarrhea, nausea, vomiting, abdominal pain, hypokalemia, and thrombocytopenia were frequently reported treatment-emergent adverse events.

In clinical studies of OPC and refractory OPC, adverse events were reported more frequently in the pool of patients with refractory OPC. The most commonly reported serious adverse events in refractory OPC patients included fever (13%) and neutropenia (10%).